Growing patient pools across mid and low income countries continue to leverage decent investments in global antibiotics market as pharmaceutical veterans seek novel geographical roadmap to address unmet medical needs. However, the situation is also leading towards high pricing caps and emergence of generic, counterfeit products.

Emerging countries such as India is making headways into antibiotics market with novel formulations. However, high pricing is likely to make inroads for several generic products. Organizations such as India based National Pharmaceutical Pricing Authority has finalized va

Growing patient pools across mid and low income countries continue to leverage decent investments in global antibiotics market as pharmaceutical veterans seek novel geographical roadmap to address unmet medical needs. However, the situation is also leading towards high pricing caps and emergence of generic, counterfeit products.

Emerging countries such as India is making headways into antibiotics market with novel formulations. However, high pricing is likely to make inroads for several generic products. Organizations such as India based National Pharmaceutical Pricing Authority has finalized valuation of a few antibiotic blockbusters. In this light, high end anti HIV medicine as well as antibiotic for epileptic have been recently finalized. Heterolabs produced HIV drug comprising Tenofovir, Bictegravir, and Emtricitabine which is marketed as Taffic is likely to be sold at Rs. 130.61.

As antibiotic drug manufacturing is tedious marketing them at high prices is common to keep further R&D expeditions in antibiotics space flourishing. However, this leads to generic formulations and thus snubbing the market share of blog buster antibiotic drugs. The challenge in tandem with proliferating risks of antibiotics resistance are likely to incur setbacks in antibiotics market.

High Pricing Format of Antibiotic Drugs Heightens Risks of generic and Counterfeit Drugs

One of the persistent challenges in antibiotics market is the prevalence e of antibiotic resistance. Stemming for excessive exposure to antibiotics, there has been a growth spurt of super bugs, leading to insufficient therapeutics. International organizations such as the United Nations has declared the massive death toll owing to antibiotic resistance likely to occur by 2050, when most common, treatable diseases such as TB can become fatal. The recent auction of biopharm major Achaogen owing to drug resistance is a substantial blow to global antibiotics market. The company's plazomicin compound despite gaining FDA approval as potent life-saving antibiotic to treat severe UTI has however received no favorable nod for bloodstream infections. The company faced hiccups from low price generic alternatives. Additionally, Darunavir produced by Emcure is likley to be sold at 160 a tablet.

US Mandates New Regulatory Framework for Antibiotic Stewardship

Antibiotics have long served as revolutionary lifesaving drugs to treat several bacteria induced anomalies and infections such as cold, flu, UTI, STDs, pneumonia and the like. Exponential rise in infections, concomitant expansions across R&D activities and novel drug emergence are likely to supplement onward growth potential in global antibiotics market in forthcoming years. Advances in antibiotic stewardship which constitute diverse strategies eying improved outcome of antibiotics for superlative patient recovery and reduced economic burden are being advocated across countries. Market challenges such as antibiotic resistance are likely to be addressed with steadfast adoption of antimicrobial stewardship programs, thus inducing steady returns in global antibiotics market.

In this regard, the CMS (The Center for Medicre and Medicaid Services) issued novel regulatory framework that necessitate hospitals across the US to facilitate stewardship programs. This development is foreseen to accurately address instances of antibiotics abuse also significantly sealing instances of healthcare associated infections, often cited during long hospital stays for chronic ailments.

On the back of fast adoption of antimicrobial stewardship programs, several hospitals have been recognized for their exemplary results. The New Jersey Dept. of Health have recent recognized the efforts of Hackensack Meridian Health for substantial adoption of Antimicrobial Stewardship programs.